Article Sidebar
Date Published:
15/11/2023
Abstract Views: 180
Views PDF: 288
Views PDF: 288
Issue
Section
Các bài báo
How to Cite
Phạm , T. A. ., Nguyễn , T. Q. ., & Nguyễn , H. T. . (2023). CASE REPORT: PATIENT WITH METASTATIC CERVICAL CANCER TREATED WITH CHEMOTHERAPY COMBINED WITH AN IMMUNE CHECKPOINT INHIBITOR. Vietnam Medical Journal, 531(2). https://doi.org/10.51298/vmj.v531i2.7178
CASE REPORT: PATIENT WITH METASTATIC CERVICAL CANCER TREATED WITH CHEMOTHERAPY COMBINED WITH AN IMMUNE CHECKPOINT INHIBITOR
Main Article Content
Abstract
In the era of immunotherapy, the combination of chemotherapy and Pembrolizumab has become the new standard treatment in recurrent and metastatic cervical cancer. We report a case of a 62-year-old female patient diagnosed with FIGO IVB cervical cancer who was treated with this regimen and achieved impressive results.
Article Details
Keywords
Cervical cancer, Immunotherapy, Pembrolizumab.
References
1. LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN. Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery. Gynecol Oncol Rep. 2017;22:16-20.
2.https://gco.iarc.fr/today/data/factsheets/populations/704-viet-nam-fact-sheets.pdf
3. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856-1867.
4. Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(21):4626-4633.
5. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(15):3113-3119.
6. Monk BJ, Sill MW, McMeekin DS, et al. Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2009; 27(28):4649-4655.
7. https://www.keytruda.com/how-does-keytruda-work/
8. Research C for DE and FDA approves pembrolizumab combination for the first-line treatment of cervical cancer. FDA. Published online January 31, 2022.
9. Tewari KS, Sill MW, Penson RT, et al. Final Overall Survival of the Phase III Randomised Trial of Chemotherapy with and without Bevacizumab for Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Lancet Lond Engl. 2017;390(10103):1654-1663.
2.https://gco.iarc.fr/today/data/factsheets/populations/704-viet-nam-fact-sheets.pdf
3. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856-1867.
4. Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(21):4626-4633.
5. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(15):3113-3119.
6. Monk BJ, Sill MW, McMeekin DS, et al. Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2009; 27(28):4649-4655.
7. https://www.keytruda.com/how-does-keytruda-work/
8. Research C for DE and FDA approves pembrolizumab combination for the first-line treatment of cervical cancer. FDA. Published online January 31, 2022.
9. Tewari KS, Sill MW, Penson RT, et al. Final Overall Survival of the Phase III Randomised Trial of Chemotherapy with and without Bevacizumab for Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Lancet Lond Engl. 2017;390(10103):1654-1663.